A trial update was recorded on May 19, 2026 for the study titled "Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma," registered as NCT00602667. Cosyntropin is associated with this trial record. The study is listed as Phase 2. Its current status is active, not recruiting. This means enrollment is not currently open, though the trial continues. No results or outcome data are included in this update. The record does not state efficacy, safety findings, or conclusions at this time. Cosyntropin remains an approved compound, and this update reflects only the administrative status of the referenced trial as of the date given. Readers interested in the study design, patient population, or further protocol details can consult the official trial listing directly. This brief reports solely the status change and associated facts as provided, without additional interpretation. For general background on cosyntropin, including its approved uses and regulatory status, readers can refer to the compound overview.
Cosyntropin-Linked Trial NCT00602667 Now Active, Not Recruiting
See the full cosyntropin overview
Source: https://clinicaltrials.gov/study/NCT00602667